Amgen to test psoriasis pill Otezla in COVID-19

Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the SARS-CoV-2 coronavirus. 

Amgen stumps up $13.4bn to claim Otezla from Celgene

Celgene gets new approval for soon-to-be-shed Otezla

BMS will shed Otezla to push Celgene takeover through

Bristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion takeover of Celgene through the financial regulatory seas.

Otezla gains NICE approval for psoriatic arthritis

Earlier decision to reject drug reversed.